Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis

Neprilysin (NEP, EP24.11), a metallopeptidase originally shown to modulate signalling events by degrading small regulatory peptides, is also an amyloid‐β‐ (Aβ) degrading enzyme. We investigated a possible role of NEP in inclusion body myositis (IBM) and other acquired and hereditary muscle disorders and found that in all myopathies NEP expression was directly associated with the degree of muscle fibre regeneration. In IBM muscle, NEP protein was also strongly accumulated in Aβ‐bearing abnormal fibres. In vitro, during the experimental differentiation of myoblasts, NEP protein expression was regulated at the post‐transcriptional level with a rapid increase in the early stage of myoblast differentiation followed by a gradual reduction thereafter, coincident with the progression of the myogenic programme. Treatment of differentiating muscle cells with the NEP inhibitor dl‐3‐mercapto‐2‐benzylpropanoylglycine resulted in impaired differentiation that was mainly associated with an abnormal regulation of Akt activation. Therefore, NEP may play an important role during muscle cell differentiation, possibly through the regulation, either directly or indirectly, of the insulin‐like growth factor I‐driven myogenic programme. In IBM muscle increased NEP may be instrumental in (i) reducing the Aβ accumulation in vulnerable fibres and (ii) promoting a repair/regenerative attempt of muscle fibres possibly through the modulation of insulin‐like growth factor I‐dependent pathways.

[1]  W. Engel,et al.  Expression of beta-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. , 1994, Experimental neurology.

[2]  N. Seidah,et al.  Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA. , 1987, The EMBO journal.

[3]  W. Engel,et al.  Difference in Expression of Phosphorylated Tau Epitopes between Sporadic Inclusion‐body Myositis and Hereditary Inclusion‐body Myopathies , 1996, Journal of neuropathology and experimental neurology.

[4]  E. Engvall,et al.  Binding of ADAM12, a Marker of Skeletal Muscle Regeneration, to the Muscle-specific Actin-binding Protein, α-Actinin-2, Is Required for Myoblast Fusion* , 2000, The Journal of Biological Chemistry.

[5]  W. Engel,et al.  Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. , 1994, The American journal of pathology.

[6]  Steven A. Johnson,et al.  Expression of β-Amyloid Precursor Protein Gene Is Developmentally Regulated in Human Muscle Fibers in Vivo and in Vitro , 1994, Experimental Neurology.

[7]  L. E. Lantry,et al.  Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts , 1995, Peptides.

[8]  H. Mori,et al.  Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form , 2003, Neuroscience Letters.

[9]  [Amino acid sequence]. , 1970, Deutsche medizinische Wochenschrift.

[10]  S. Howell,et al.  Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolism , 1995, Peptides.

[11]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[12]  H. Mizukami,et al.  Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-β Peptide in Mouse Brain , 2004, The Journal of Neuroscience.

[13]  A. D’Amico,et al.  Insulin‐like Growth Factor I in Inclusion‐Body Myositis and Human Muscle Cultures , 2004, Journal of neuropathology and experimental neurology.

[14]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[15]  M. Kerr,et al.  The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. , 1974, The Biochemical journal.

[16]  R. Baxter,et al.  Molecular distribution of IGF binding protein-5 in human serum. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  K. von Figura,et al.  Neutral endopeptidase-24.11 (enkephalinase). Biosynthesis and localization in human fibroblasts. , 1987, The Biochemical journal.

[18]  J. Labbé,et al.  cdk1- and cdk2-Mediated Phosphorylation of MyoD Ser200 in Growing C2 Myoblasts: Role in Modulating MyoD Half-Life and Myogenic Activity , 1999, Molecular and Cellular Biology.

[19]  Catherine Magill,et al.  Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression , 1998, Nature Medicine.

[20]  W. Engel,et al.  Redox factor-1 in muscle biopsies of patients with inclusion-body myositis , 2000, Neuroscience Letters.

[21]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[22]  K. Weisgraber,et al.  Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies , 1996, Annals of neurology.

[23]  S. Howell,et al.  Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. , 1995, Peptides.

[24]  Q. Wang,et al.  Role of glycosylation in transport and enzymic activity of neutral endopeptidase-24.11. , 1994, The Biochemical journal.

[25]  F. Authier,et al.  ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation. , 2005, Molecular biology of the cell.

[26]  P. Sirois,et al.  Guinea pig Clara cells secrete endothelin 1 through a phosphoramidon-sensitive pathway. , 1996, American journal of respiratory cell and molecular biology.

[27]  T. Terasaki,et al.  Brain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain , 2004, The Journal of Neuroscience.

[28]  Masanori Kato,et al.  Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (Aβ) deposition , 2001, Brain Research.

[29]  D. Stokoe,et al.  Akt phosphorylation is not sufficient for insulin-like growth factor-stimulated myogenin expression but must be accompanied by down-regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase phosphorylation. , 2004, Endocrinology.

[30]  Qing Xu,et al.  The Insulin-like Growth Factor-Phosphatidylinositol 3-Kinase-Akt Signaling Pathway Regulates Myogenin Expression in Normal Myogenic Cells but Not in Rhabdomyosarcoma-derived RD Cells* , 2000, The Journal of Biological Chemistry.

[31]  M. Albrecht,et al.  Independent signals determine the subcellular localization of NEP in prostate cancer cells. , 2003, Biochemical and biophysical research communications.

[32]  K. Suzuki,et al.  Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. , 1995, Endocrinology.

[33]  W. Strittmatter,et al.  Specific blockers of myoblast fusion inhibit a soluble and not the membrane-associated metalloendoprotease in myoblasts. , 1984, The Journal of biological chemistry.

[34]  C. Stewart,et al.  Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism , 1996, The Journal of cell biology.

[35]  D. Coates,et al.  The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[36]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[37]  L. F. Kolakowski,et al.  Neutral endopeptidase modulation of septic shock , 1995, The Journal of experimental medicine.

[38]  P. Mcgeer,et al.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide , 2001, Neuroscience Letters.

[39]  C. Stewart,et al.  Role of insulin‐like growth factor binding protein‐3 (IGFBP‐3) in the differentiation of primary human adult skeletal myoblasts , 2003, Journal of cellular physiology.

[40]  J R Florini,et al.  Growth hormone and the insulin-like growth factor system in myogenesis. , 1996, Endocrine reviews.

[41]  E. Carmeli,et al.  Matrix metalloproteinases and skeletal muscle: A brief review , 2004, Muscle & nerve.

[42]  F. Authier,et al.  ADAM12 and α9β1 Integrin Are Instrumental in Human Myogenic Cell Differentiation , 2004 .

[43]  M. Georgescu,et al.  Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. , 2004, Cancer cell.

[44]  S. Kiryu-Seo,et al.  Damage-induced neuronal endopeptidase (DINE) is a unique metallopeptidase expressed in response to neuronal damage and activates superoxide scavengers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. E. Lantry,et al.  Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts , 1996, Peptides.

[46]  T. Terasaki,et al.  Brain insulin impairs amyloid-beta(1-40) clearance from the brain. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  F. Gage,et al.  Neprilysin regulates amyloid β peptide levels , 2007, Journal of Molecular Neuroscience.

[48]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[49]  T. Iwatsubo,et al.  Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.

[50]  Winter,et al.  NCAM, vimentin and neonatal myosin heavy chain expression in human muscle diseases , 1999, Neuropathology and applied neurobiology.

[51]  F. Giancotti,et al.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. , 2000, The Journal of clinical investigation.

[52]  C. Pinset,et al.  Cell Cycle–regulated Expression of the Muscle Determination Factor Myf5 in Proliferating Myoblasts , 1998, The Journal of cell biology.

[53]  T. Saido,et al.  Metabolic regulation of brain Abeta by neprilysin. , 2001, Science.

[54]  T. Nam,et al.  Characterization and determination of the relative abundance of two types of insulin-like growth factor binding protein-5 proteases that are secreted by human fibroblasts. , 1996, Endocrinology.

[55]  T. J. Baldwin,et al.  Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules , 1996, Journal of cellular biochemistry.

[56]  Yama Akbari,et al.  Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. , 2005, Neurobiology of aging.

[57]  P. Vogt,et al.  Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Y. Nabeshima,et al.  A metalloprotease-disintegrin participating in myoblast fusion , 1995, Nature.

[59]  W. Strittmatter,et al.  Rat myoblast fusion requires metalloendoprotease activity , 1983, Cell.

[60]  F. Gage,et al.  Neprilysin regulates amyloid Beta peptide levels. , 2004, Journal of molecular neuroscience : MN.

[61]  W. Engel,et al.  Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms , 2002, Current opinion in neurology.

[62]  W. Buurman,et al.  Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. , 1999, Cytokine & growth factor reviews.

[63]  Gregory R Adams,et al.  Autocrine and/or paracrine insulin-like growth factor-I activity in skeletal muscle. , 2002, Clinical orthopaedics and related research.

[64]  R. Vos,et al.  Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis , 2003, The Lancet.

[65]  J. Florini,et al.  The Mitogenic and Myogenic Actions of Insulin-like Growth Factors Utilize Distinct Signaling Pathways* , 1997, The Journal of Biological Chemistry.

[66]  A. Musarò,et al.  Maturation of the Myogenic Program Is Induced by Postmitotic Expression of Insulin-Like Growth Factor I , 1999, Molecular and Cellular Biology.

[67]  C. Holding,et al.  Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Schwartz,et al.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice , 1980, Nature.

[69]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[70]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.